COVID SCIENCE – High blood thickness increases risk of death; some problems with flu-COVID vaccines together

Band Nancy Lapid

July 18 (Reuters)Here is a summary of some recent studies on COVID-19. They include research that deserves further study to corroborate the findings and that has not yet been certified by peer review.

Blood thickness linked to risk of death in severe COVID-19 cases

Patients hospitalized with COVID-19 whose blood circulates less freely than normal are at higher risk of death from complications, a US study has shown. The findings indicate that measuring blood viscosity, or blood thickness, should be an integral part of medical workup for these patients, the researchers said.

High blood viscosity impairs flow to small vessels and increases the risk of blood clots, researchers noted in the study published Monday in the Journal of the American College of Cardiology. Data on 5,621 COVID-19 patients treated at six New York-area hospitals between February 2020 and November 2021 showed that patients with high viscosity had 38% to 60% higher mortality rates than those with low blood viscosity. Inflammation associated with COVID-19 likely contributes to high viscosity, which in turn can damage blood vessel walls and clog arteries, the researchers say.

“This study demonstrates the importance of checking blood viscosity in COVID-19 patients early in hospital admission, which is easily achieved through routine laboratory work,” said Dr. Robert Rosenson of Mount Sinai Health System in a statement. His team called for further studies to see if measures to reduce blood viscosity, such as treatment with blood thinners, would be helpful.

Few excessive effects of COVID-19 reminder, flu shot together

People who get the flu shot at the same time as a booster of the COVID-19 mRNA vaccine are only slightly more likely to report side effects than people who get the booster alone, US researchers have found. Previous studies have found that giving influenza vaccines and COVID-19 vaccines at the same time does not make either less effective and may be more convenient. As reported Friday in the newspaper Open JAMA Network, researchers followed 981,099 American adolescents and adults who received vaccine boosters with or without the flu vaccine in September or October 2021. The following week, reports from study participants of a reaction “ systemic” such as fatigue, headache or body aches were 8% higher for those who received the flu vaccine and the Pfizer-BioNTech booster simultaneously and 11% higher for those who received the flu vaccine and a Moderna booster, compared to the risk in people who only received a booster of the mRNA vaccine. Based on the results, “clinicians can confidently inform patients that co-administration of the COVID-19 booster and the seasonal influenza vaccine is both safe and associated with only a small increase in adverse events compared to the COVID-19 booster alone,” a separate team of researchers wrote in an accompanying editorial.

Children allergic to vaccines safely receive injections Pfizer

Pfizer’s COVID-19 mRNA vaccine can be safely given to children even after a suspected allergic reaction to the first dose or a suspected allergy to the vaccine ingredients polyethylene glycol (PEG) or polysorbate, according to immunologists. Other allergists have previously reported that second doses can be given to adults suspected of reacting to the first dose. The results of a study involving a small number of children were published on Wednesday in The Journal of Allergy and Clinical Immunology: In Practice. At a vaccine clinic, nine children were evaluated after having an allergic reaction to the first dose of the vaccine, including three who suffered life-threatening anaphylaxis. The nine children – including one who was premedicated – eventually received the second dose “with little or no symptoms”, the researchers said. Three other children with a history of potential reactions to PEG/polysorbate elected to receive the vaccine at the clinic and tolerated both doses without allergic symptoms.

“Any child who experiences potential anaphylaxis after vaccination should definitely be evaluated,” said study leader Dr. Joel Brooks, of Children’s National Hospital in Washington, in a press release. “Benefits and risks must be carefully weighed when it comes to a second dose. However, we demonstrated that for this study, most initial allergic reactions did not meet the criteria for anaphylaxis and our participants were able to tolerate a second dose of the vaccine.”

Click for a Reuters Global COVID-19 Tracker and for one Reuters COVID-19 Vaccination Tracker.

COVID-19 Global Tracking

COVID-19 Vaccination Tracking

(Reporting by Nancy Lapid; Editing by Will Dunham)

(([email protected]))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Comments are closed.